Regulus Therapeutics Inc (RGLS)
2.22
-0.04
(-1.77%)
USD |
NASDAQ |
Apr 24, 16:00
2.24
+0.02
(+0.90%)
After-Hours: 20:00
Regulus Therapeutics Free Cash Flow (Quarterly): -6.196M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -6.196M |
| September 30, 2023 | -6.818M |
| June 30, 2023 | -6.252M |
| March 31, 2023 | -8.115M |
| December 31, 2022 | -6.316M |
| September 30, 2022 | -6.736M |
| June 30, 2022 | -6.352M |
| March 31, 2022 | -6.483M |
| December 31, 2021 | -7.872M |
| September 30, 2021 | -5.588M |
| June 30, 2021 | -5.155M |
| March 31, 2021 | -5.764M |
| December 31, 2020 | 3.189M |
| September 30, 2020 | -4.508M |
| June 30, 2020 | -5.226M |
| March 31, 2020 | -6.002M |
| December 31, 2019 | -5.036M |
| September 30, 2019 | -4.897M |
| June 30, 2019 | -5.699M |
| March 31, 2019 | -4.433M |
| December 31, 2018 | -4.017M |
| September 30, 2018 | -11.47M |
| June 30, 2018 | -12.21M |
| March 31, 2018 | -15.60M |
| Date | Value |
|---|---|
| December 31, 2017 | -11.19M |
| September 30, 2017 | -11.76M |
| June 30, 2017 | -17.31M |
| March 31, 2017 | -18.84M |
| December 31, 2016 | -15.28M |
| September 30, 2016 | -15.99M |
| June 30, 2016 | -17.24M |
| March 31, 2016 | -9.336M |
| December 31, 2015 | -17.56M |
| September 30, 2015 | -12.28M |
| June 30, 2015 | -9.949M |
| March 31, 2015 | -11.50M |
| December 31, 2014 | -11.70M |
| September 30, 2014 | -9.21M |
| June 30, 2014 | -10.71M |
| March 31, 2014 | -9.104M |
| December 31, 2013 | -9.495M |
| September 30, 2013 | -4.719M |
| June 30, 2013 | -7.692M |
| March 31, 2013 | -7.259M |
| December 31, 2012 | 0.334M |
| September 30, 2012 | 0.18M |
| June 30, 2012 | -5.157M |
| March 31, 2012 | -5.504M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-8.115M
Minimum
Mar 2023
3.189M
Maximum
Dec 2020
-5.570M
Average
-6.002M
Median
Mar 2020
Free Cash Flow (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 85.39M |
| ADMA Biologics Inc | 16.19M |
| FibroGen Inc | -18.57M |
| Protara Therapeutics Inc | -8.70M |
| Amylyx Pharmaceuticals Inc | 13.20M |